b.) Amendment to the Claims:

Claims 1-3 (Cancelled).

4. (Currently Amended) ~~The method according to any one of claims 1 to 3~~ A method of manufacturing a Tuj1 positive neuron which comprises culturing a neural stem cell in the presence of a substance that inhibits glycogen synthase kinase-3 (GSK-3) to allow neogenesis of the neuron, and collecting the neuron from the culture, wherein the substance that inhibits the activity of GSK-3 is lithium or a pharmacologically acceptable salt thereof.

5. (Currently Amended) ~~The method according to any one of claims 1 to 3~~ A method of manufacturing a Tuj1 positive neuron which comprises culturing a neural stem cell in the presence of a substance that inhibits glycogen synthase kinase-3 (GSK-3) to allow neogenesis of the neuron, and collecting the neuron from the culture, wherein the substance that inhibits the activity of GSK-3 ~~comprises~~ is a bisindolylmaleimide derivative, ~~a 3-aryl-4-indolylmaleimide derivative, an indolocarbazole derivative, an indolo[3,2-d][1]benzazepin-6(5H)-one derivative or an indirubin derivative,~~ or a pharmacologically acceptable salt thereof.

6. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 5, wherein the ~~substance that inhibits the activity of GSK-3 comprises a compound~~ bisindolylmaleimide derivative is represented by ~~the~~ formula (I):



(I)

[wherein n and m ~~may be the same or different, and~~ independently represent an integer of 1 to 3; R^1, R^3 and R^4 ~~may be the same or different, and~~ independently represent hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, $-COR^6$ (wherein R^6 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl), $-COOR^7$ (wherein R^7 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl) or $-OR^8$ (wherein R^8 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl); R^2 and R^5 ~~may be the same or different, and~~ independently represent hydrogen, substituted or unsubstituted lower alkyl, a substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aryl, carboxy, halogen, hydroxy, nitro, amino, or mono- or di-lower alkylamino; and when n and m are 2 or 3, each of R^2 and R^5 may be the same or different],

~~a compound represented by the formula (II):~~



(II)

~~(wherein na, ma, R^{1A}, R^{2A}, R^{3A} and R^{5A} are as defined for the aforementioned n, m, R^1, R^2, R^3 and R^5, respectively, or~~

~~a compound represented by the formula (III):~~



(III)

~~[wherein nb, mb, R^{1B}, R^{2B} and R^{5B} are as defined for the aforementioned n, m, R^1, R^2 and R^5, respectively; R^{3B} and R^{4B} may be the same or different, and represent hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, $-COR^6$, $-COOR^7$ or $-OR^8$, or R^{3B} and R^{4B} together form~~



(A)

~~(wherein k represents 1 or 2; X represents CH_2, NH, an oxygen atom or a sulfur atom; R^9 represents hydroxy, carboxy, carbamoyl or lower alkoxycarbonyl)];~~

or a pharmacologically acceptable salt thereof.

7. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 6, wherein the ~~substance that inhibits the activity of GSK-3 is a compound~~ bisindolylmaleimide derivative is represented by ~~the~~ formula (Ia):



(Ia)

(wherein R^{2a} represents hydrogen, lower alkoxy, lower alkoxycarbonyl, aryl or nitro; and R^{3a} and R^{4a} ~~may be the same or different, and~~ independently represent substituted or unsubstituted lower alkyl),

or a pharmacologically acceptable salt thereof.

8. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 44, wherein the ~~substance that inhibits the activity of GSK-3 is a compound~~ bisindolylmaleimide derivative is represented by ~~the~~ formula (IIa):



(IIa)

(wherein R^{3Aa} represents substituted or unsubstituted lower alkyl; and R^{5Aa} represents halogen),

or a pharmacologically acceptable salt thereof.

9. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 47, wherein the ~~substance that inhibits the activity of GSK-3 is a compound~~ indolocarbazole derivative is represented by ~~the~~ formula (IIIa):



(IIIa)

or ~~, or~~ a pharmacologically acceptable salt thereof.

10. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 6, wherein the ~~substance that inhibits the activity of GSK-3 is a compound~~ bisindolylmaleimide derivative is selected from the group consisting of 3,4-bis(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-(1-methylindole-3-yl)-4-(1-propylindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-cyanopropyl)indole-3-yl]-4-(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-aminopropyl)indole-3-yl]-4-(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-carboxypropyl)indole-3-yl]-4-(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-carbamoylpropyl)indole-3-yl]-4-(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-aminopropyl)indole-3-yl]-4-(1-methyl-5-propyloxyindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)indole-3-yl]-4-(1-methyl-5-phenylindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-aminopropyl)indole-3-yl]-4-(1-methyl-5-phenylindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)indole-3-yl]-4-(1-methyl-5-methoxycarbonylindole-3-yl)-1H-pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)indole-3-yl]-4-

(1-methyl-5-nitroindole-3-yl)-1H-pyrrole-2,5-dione, and 3-(1-methylindole-3-yl)-4-[1-(3-hydroxypropyl)-5-nitroindole-3-yl]-1H-pyrrole-2,5-dione, ~~3-(2-chlorophenyl)-4-(1-methyl-indole-3-yl)-1H-pyrrole-2,5-dione, 3-(2,4-dichlorophenyl)-4-(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-(2-chlorophenyl)-4-[1-(3-hydroxypropyl)indole-3-yl]-1H-pyrrole-2,5-dione, 4-[1-(3-aminopropyl)indole-3-yl]-3-(2-chlorophenyl)-1H-pyrrole-2,5-dione and~~



or ~~, or~~ a pharmacologically acceptable salt thereof.

11. (Currently Amended) ~~The method according to any one of claims 1 to 3~~ A method of manufacturing a Tuj1 positive neuron which comprises culturing a neural stem cell in the presence of a substance that inhibits glycogen synthase kinase-3 (GSK-3) to allow neogenesis of the neuron, and collecting the neuron from the culture, wherein the substance that inhibits the activity of GSK-3 ~~comprises~~ is a compound represented by ~~the~~ formula (IV):



(IV)

[wherein A is oxygen or sulfur coupled ~~to the right~~ by a single or double bond; R^{10} is selected from the group consisting of hydrogen, aryl, lower ~~aliphatic substituents, particularly~~ alkyl and lower alkyl ester; R^{11}-R^{14} are independently selected from the group consisting of alkoxy, amino, acyl, ~~aliphatic substituents, particularly~~ alkyl, alkenyl and alkinyl substituents, ~~aliphatic alcohols, particularly~~ alkyl alcohols, ~~aliphatic nitriles, particularly~~ alkyl nitriles, cyano, nitro, carboxyl, halogen, hydrogen, hydroxyl, imino and α,β-unsaturated ketones; R^{15}-R^{18} are independently selected from the group consisting of ~~aliphatic substituents, particularly~~ alkyl, alkenyl and alkinyl substituents, ~~particularly lower aliphatic substituents, alipahatic alcohols, particularly~~ alkyl alcohols, alkoxy, acyl, cyano, nitro, epoxy, haloalkyl groups, halogen, hydrogen and hydroxyl; and R^{19} is selected from the group consisting of ~~aliphatic groups, particularly~~ lower alkyl groups, ~~aliphatic alcohols, particularly~~ alkyl alcohols, carboxylic acids and hydrogen],

or a pharmacologically acceptable salt thereof.

12. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 11, wherein the substance that inhibits the activity of GSK-3 is ~~a compound~~ selected from the group consisting of 7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one,

2-bromo-7,12-dihydro-indolo[3,2-d][l]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-chloro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 11-chloro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 10-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 8-bromo-6,11-dihydro-thieno[3',2':2,3]azepino[4,5-b]indol-5(4H)-one, 9-bromo-7,12-dihydro-4-methoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-4-hydroxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-4-methoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-2,3-dimethoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-2,3-dihydroxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-2,3-dimethoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-9-trifluormethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-2,3-dimethoxy-9-trifluoromethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 2-bromo-7,12-dihydro-9-trifluoromethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-indolo[3,2d][1]benzazepin-6(5H)-thione, 9-bromo-5,12-bis-(t-butyloxycarbonyl)-7,12-dihydro-indolo[3,2-d][1]-benzazepin-6(5H)-one, 9-bromo-12-(t-butyloxycarbonyl)-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-5,7-bis-(t-butyloxycarbonyl)-7,12-dihydro-indolo-[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-5,7,12-tri-(t-butyloxycarbonyl)-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-5-methyloxycarbonylmethyl-indolo[3,2-d][l]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-12-methyloxycarbonylmethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-12-(2-hydroxyethyl)-indolo[3,2-d][1]benzazepin-6(5H)-one, 2,9-dibromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 8,10-dichloro-7,12-dihydro-indolo[3,2d][1]benzazepin-6(5H)-one, 9-cyano-7,12-dihydro-indolo[3,2-d][1]benzazepin-

6(5H)-one, 9-bromo-7,12-dihydro-5-methyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 5-benzyl-9-bromo-7,12-dihydro-5-methyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-12-methyl-indolo[3,2-d][l]benzazepin-6(5H)-one, 9-bromo-12-ethyl-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-12-(2-propenyl)-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-9-methyl-indolo[3,2-d][1]-benzazepin-6(5H)-one, 7,12-dihydro-9-methoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-fluoro-7,12-dihydro-12-(2-propenyl)-indolo[3,2-d][1]benzazepin-6(5H)-one, 11-bromo-7,12-dihydro-indolo[3,2d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-2-(methyliminoamine)-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-2-(carboxylic acid)-indolo[3,2-d][l]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-10-hydroxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-11-hydroxymethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-4-hydroxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-2,3-dihydroxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 2,3-dimethoxy-9-nitro-7,12-dihydro-indolo[3,2d][1]benzazepin-6(5H)-one, 9-cyano-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 2,3-dimethoxy-9-cyano-7,12-dihydro-indolo[3,2-d][l]benzazepin-6(5H)-one, 9-nitro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 3-(6-oxo-9-trifluoromethyl-5,6,7,12-tetrahydro-indolo[3,2-d][1]benzazepin-2-yl)-propionitrile, 2-bromo-9-nitro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 3-(6-oxo-9-trifluoromethyl-5,6,7,12-tetrahydro-indolo[3,2-d][1]benzazepin-2-yl)acrylonitrile, 2-(3-hydroxy-l-propinyl)-9-trifluoromethyl-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 2-iodo-9-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 2-(3-oxo-l-butenyl)-9-trifluoromethyl-7,12-tetrahydro-indolo[3,2-d][l]benzazepin-6(5H)-one, 8-chloro-6,11-

dihydro-thieno[3',2':2,3]azepino[4,5-b]indol-5(4H)-one, 2-iodo-9-trifluoromethyl-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-pyrido[3',2':4,5]pyrrolo[3,2-d][l]benzazepin-6(5H)-one, 11-methyl-7,12-dihydro-indolo[3,2-d][1]-benzazepin-6(5H)-one, 2-[2-(1-hydroxycyclohexyl)ethinyl]-9-trifluoromethyl-7,12-dihydro-indolo[3,2-d][l]benzazepin-6(5H)-one, 2-cyano-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 2-iodo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 11-ethyl-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 8-methyl-6,11-dihydro-thieno[3',2':2,3]azepino[4,5-b]indol-5(4H)-one and 3-(6-oxo-9-trifluoromethyl-5,6,7,12-tetrahydro-indolo[3,2-d][1]benzazepin-2-yl)acrylic ~~acid, methyl~~ acid methyl ester,

or a pharmacologically acceptable salt thereof.

13. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 11, wherein the substance that inhibits the activity of GSK-3 is selected from the group consisting of 9-cyano-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-2,3-dimethoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 2-bromo-7,12-dihydro-9-trifluoromethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-2,3-dimethoxy-9-trifluoromethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 2,9-dibromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-9-trifluoromethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-chloro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 8-bromo-6,11-dihydro-thieno[3',2':2,3]azepino[4,5-b]indole-5(4H)-one, 7,12-dihydro-9-methoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 10-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 11-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 11-chloro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-

one, 9-fluoro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-methyl-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-thione, 8,10-dichloro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-12-(2-hydroxyethyl)-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-2,3-dihydroxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 2-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-2,3-dimethoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-12-methyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-5-methyloxycarbonylmethyl-indolo[3,2-d][1]benzazepin-6(5H)-one and 7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one,

or a pharmacologically acceptable salt thereof.

14. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 11, wherein the substance that inhibits the activity of GSK-3 is selected from the group consisting of 9-cyano-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-2,3-dimethoxy-indolo[3,2-d][1]benzazepin-6(5H)-one, 2-bromo-7,12-dihydro-9-trifluoromethyl-indolo[3,2-d][l]benzazepin-6(5H)-one, 7,12-dihydro-2,3-dimethoxy-9-trifluoromethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 2,9-dibromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 7,12-dihydro-9-trifluormethyl-indolo[3,2-d][1]benzazepin-6(5H)-one, 9-chloro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, 8-bromo-6,11-dihydro-thieno[3',2':2,3]azepino[4,5-b]indol-5(4H)-one, 7,12-dihydro-9-methoxy-indolo[3,2-d][1]benzazepin-6(5H)-one,

or a pharmacologically acceptable salt thereof.

15. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 11, wherein the substance that inhibits the activity of GSK-3 is 9-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one, or

a pharmacologically acceptable salt thereof.

16. (Currently Amended) ~~The method according to any one of claims 1 to 3~~ A method of manufacturing a Tuj1 positive neuron which comprises culturing a neural stem cell in the presence of a substance that inhibits glycogen synthase kinase-3 (GSK-3) to allow neogenesis of the neuron, and collecting the neuron from the culture, wherein the substance that inhibits the activity of GSK-3 ~~comprises~~ is a compound represented by the formula (V):



(V)

[wherein R^{20} and R^{25} ~~may be the same or different and~~ independently represent hydrogen; halogen; a hydroxy group; a methylene hydroxy group; a straight or branched C_1 to C_{18}-alkyl or straight or branched C_1 to C_{18}-alkoxy or a methylenealkoxy group (wherein the alkoxy is straight or branched C_1 to C_{18}); a cycloalkyl group having 3 to 7 carbon which may have one or more ~~heteroatoms a~~ heteroatoms; a substituted or unsubstituted aryl, aralkyl or aryloxy group which may have one or more heteroatoms; a mono-, di- or trialkylsilyl group each independently having 1 to 6 carbon atoms within the

straight or branched alkyl group; a mono-, di- or triarylsilyl group each independently having a substituted or unsubstituted aryl group; a trifluoromethyl group; -COM; -COOM; or a $-CH_2COOM$ group (wherein M represents hydrogen, a straight or branched C_1 to C_{18}-alkyl group which may be substituted with one or more hydroxy and/or amino groups, or an aryl group, which may be substituted with one or more halogen, alkyl groups or alkoxy groups which may have one or more heteroatoms; an $-NR^{30}R^{31}$ group (wherein R^{30} and R^{31} ~~may be the same or different and~~ independently represent a hydrogen atom, a C_1 to C_{18} straight or branched alkyl group which may be additionally substituted with one or more hydroxy and/or amino groups, a substituted or unsubstituted aryl group which may have one or more heteroatoms); an acyl group; a $-CH_2-NR^{30}R^{31}$ methyleneamino group; a benzyl group which may have one or more heteroatoms in the benzene ring; a methylenecycloalkyl group having 3 to 7 carbon atoms which may have one or more heteroatoms; a physiological amino acid group coupled to a nitrogen atom as an amide; an O-glycoside or N-glycoside having glycoside of which being selected from monosaccharides or disaccharides; or a methylenesulfonate group; R^{21}, R^{22}, R^{23}, R^{24}, R^{26}, R^{27}, R^{28} and R^{29} may be the same or different and represent hydrogen; halogen; a hydroxy group; a nitroso group; a nitro group; an alkoxy group; a straight or branched C_1 to C_{18} alkyl group which may be substituted with one or more hydroxy and/or amino groups; a substituted or unsubstituted aryl group which may have one or more heteroatoms; a substituted or unsubstituted aralkyl group which may have one or more heteroatoms; a substituted or unsubstituted aryloxy group which may have one or more heteroatoms; a substituted or unsubstituted methylenearyloxy group which may have one or more heteroatoms; a cycloalkyl group having 3 to 7 carbon atoms which may have one or more

heteroatoms; a methylenecycloalkyl group having 3 to 7 carbon atoms which may have one or more heteroatoms; a trifluoromethyl group; -COM; -COOM; or a CH_2COOM group (wherein M represents hydrogen, a straight or branched C_1 to C_{18}-alkyl group which may be additionally substituted with one or more hydroxy and/or amino groups, or an aryl group, which may be substituted with one or more halogen atoms, alkyl groups or alkoxy groups which may have one or more heteroatoms); an $-NR^{30}R^{31}$ group (wherein R^{30} and R^{31} ~~which may be the same or different and~~ independently represent hydrogen, a straight or branched C_1 to C_{18}-alkyl group which may be additionally substituted with one or more hydroxy and/or amino groups, a substituted or unsubstituted aryl group which may have one or more heteroatoms, ~~an acyl group, or form a part of cycloalkyl having 3 to 7 carbon atoms with the nitrogen atom which may have one or more heteroatoms~~); a $-CONR^{30}R^{31}$ group; a hydroxylamino group; a phosphate group; a phosphonate group; a sulfate group; a sulfonate group; a sulfonamide group; an $-SO_2NR^{30}R^{31}$ group; an $-N=N-R^{32}$ azo group (wherein R^{32} represents an aromatic group which may be substituted with one or more carboxyl, phosphoryl or sulfonate groups, or an O-glycoside or N-glycoside group having glycoside of which being selected from monosaccharides or disaccharides); or R^{20} and R^{24}, and R^{25} and R^{29} together form a ring which may have one to four CH_2 groups each independently substituted, respectively; Y and Z ~~may be the same or different and~~ independently represent an oxygen atom; a sulfur atom; a selenium atom; a tellurium atom; an NR^{33} group (wherein R^{33} represents hydrogen, a straight or branched C_1 to C_{18} alkyl group which may be substituted with one or more carboxyl, phosphoryl or sulfonate groups, a substituted or unsubstituted aryl group which may have one or more heteroatoms, an aralkyl group or a sulfonate group); or $-NOR^{33}$],

or a pharmacologically acceptable salt thereof.

17. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 16, wherein the substance that inhibits the activity of GSK-3 is ~~a compound~~ selected from the group consisting of indirubin, 5-iodo-indirubin, 5-bromo-indirubin, 5-chloro-indirubin, 5-fluoro-indirubin, 5-methyl-indirubin, 5-nitro-indirubin, 5-SO_3H-indirubin, 5'-bromo-indirubin, 5-5'-dibromo-indirubin and 5'-bromo-indirubin 5-sulfonic acid,

or a pharmacologically acceptable salt thereof.

18. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 16, wherein the substance that inhibits the activity of GSK-3 is ~~a compound~~ selected from the group consisting of indirubin-3'-monooxime, 5-iodo-indirubin-3'-monooxime and 5-SO_3Na-indirubin-3'-monooxime,

or a pharmacologically acceptable salt thereof.

19. (Currently Amended) The method according to ~~any one of claims 1 to 3~~ claim 16, wherein the substance that inhibits the activity of GSK-3 is indirubin-3'-~~monooxime~~ monooxime,

or a pharmacologically acceptable salt thereof.

Claims 20-41 (Cancelled)

42. (New) A method of manufacturing a Tuj1 positive neuron which comprises culturing a neural stem cell in the presence of a substance that inhibits glycogen synthase kinase-3 (GSK-3) to allow neogenesis of the neuron, and collecting the neuron from the culture, wherein the substance that inhibits the activity of GSK-3 is siRNA selected from the group consisting of SEQ ID NOS: 15-17.

43. (New) A method of manufacturing a tuj1 positive neuron which comprises culturing a neural stem cell in the presence of an active agent to allow neurogenesis of neuron, and collecting the neuron from the culture, wherein the active agent consists of a 3-aryl-4-indolylmaleimide derivative,

or a pharmacologically acceptable salt thereof.

44. (New) The method according to claim 43, wherein the 3-aryl-4-indolylmaleimide derivative is represented by formula (II):



(II)

[wherein na and ma independently represent an integer of 1 to 3; R^{1A} and R^{3A} independently represent hydrogen, substituted or unsubstituted lower alkyl, substituted

or unsubstituted lower alkenyl, -COR^6 (wherein R^6 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl), -$COOR^7$ (wherein R^7 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl) or -OR^8 (wherein R^8 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl); R^{2A} and R^{5A} independently represent hydrogen, substituted or unsubstituted lower alkyl, a substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aryl, carboxy, halogen, hydroxy, nitro, amino, or mono- or di-lower alkylamino; and when n and m are 2 or 3, each of R^2 and R^5 may be the same or different],

or a pharmacologically acceptable salt thereof.

45. (New) The method according to claim 44, wherein the 3-aryl-4-indolylmaleimide derivative is 3-(2-chlorophenyl)-4-(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-(2,4-dichlorophenyl)-4-(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-(2-chlorophenyl)-4-[1-(3-hydroxypropyl)indole-3-yl]-1H-pyrrole-2,5-dione, or 4-[1-(3-aminopropyl)indole-3-yl]-3-(2-chlorophenyl)-1H-pyrrole-2,5-dione,

or a pharmacologically acceptable salt thereof.

46. (New) The method according to claim 9, wherein the indolocarbazole derivative is represented by formula (IIIb)



(IIIb)

or a pharmacologically acceptable salt thereof.

47. (New) A method of manufacturing a tuj1 positive neuron which comprises culturing a neural stem cell in the presence of a substance that inhibits glycogen synthase kinase-3 (GSK-3) to allow neurogenesis of neuron, and collecting the neuron from the culture, wherein the substance that inhibits the activity of GSK-3 is a an indolocarbazole derivative,

or a pharmacologically acceptable salt thereof.

48. (New) The method according to claim 47, wherein the indolocarbazole derivative is represented by formula (III):



(III)

[wherein nb and mb independently represent an integer of 1 to 3; R^{1B} represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, -COR^6 (wherein R^6 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl), -$COOR^7$ (wherein R^7 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl) or -OR^8 (wherein R^8 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl); R^{2B} and R^{5B} independently represent hydrogen, substituted or unsubstituted lower alkyl, a substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aryl, carboxy, halogen, hydroxy, nitro, amino, or mono- or di-lower alkylamino; and when n and m are 2 or 3, each of R^2 and R^5 may be the same or different; R^{3B} and R^{4B} independently represent hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, -COR^6, -$COOR^7$ or -OR^8, or R^{3B} and R^{4B} together form



(A)

(wherein k represents 1 or 2; X represents CH_2, NH, an oxygen atom or a sulfur atom; R^9 represents hydroxy, carboxy, carbamoyl or lower alkoxycarbonyl)];

or a pharmacologically acceptable salt thereof.

49. (New) A method manufacturing a tuj1 positive neuron which comprises culturing a neural stem cell in the presence of a substance that inhibits glycogen synthase kinase-3 (GSK-3) to allow neurogenesis of neuron, and collecting the neuron from the culture, wherein the substance that inhibits the activity of GSK-3 is an indolo[3,2-d][1]benzazepin-6(5H)-one derivative,

or a pharmacologically acceptable salt thereof.

50. (New) A method manufacturing a tuj1 positive neuron which comprises culturing a neural stem cell in the presence of a substance that inhibits glycogen synthase kinase-3 (GSK-3) to allow neurogenesis of neuron, and collecting the neuron from the culture, wherein the substance that inhibits the activity of GSK-3 is an indirubin derivative,

or a pharmacologically acceptable salt thereof.

51. (New) A method of manufacturing a tuj1 positive neuron which comprises culturing a neural stem cell in the presence of an active agent to allow neurogenesis of neuron, and collecting the neuron from the culture, wherein the active agent comprises a 3-aryl-4-indolylmaleimide derivative represented by formula (II):



(II)

[wherein na and ma independently represent an integer of 1 to 3; R^{1A} and R^{3A} independently represent hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, -COR^6 (wherein R^6 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl), -$COOR^7$ (wherein R^7 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl) or -OR^8 (wherein R^8 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl); R^{2A} and R^{5A} independently represent hydrogen, substituted or unsubstituted lower alkyl, a substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aryl, carboxy, halogen, hydroxy, nitro, amino, or mono- or di-lower alkylamino; and when n and m are 2 or 3, each of R^2 and R^5 may be the same or different],

or a pharmacologically acceptable salt thereof.

52. (New) The method according to claim 51, wherein the 3-aryl-4-indolylmaleimide derivative is 3-(2-chlorophenyl)-4-(1-methylindole-3-yl)-1H-pyrrole-

2,5-dione, 3-(2,4-dichlorophenyl)-4-(1-methylindole-3-yl)-1H-pyrrole-2,5-dione, 3-(2-chlorophenyl)-4-[1-(3-hydroxypropyl)indole-3-yl]-1H-pyrrole-2,5-dione, or 4-[1-(3-aminopropyl)indole-3-yl]-3-(2-chlorophenyl)-1H-pyrrole-2,5-dione,

or a pharmacologically acceptable salt thereof.